CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Earlier this week, semaglutide drugs Ozempic and Wegovy were made available for prescription in New Zealand. Semaglutide ...

Weight loss injections are now available on the NHS but experts warn thousands of patients may be vulnerable to serious side ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

I hear a lot of talk around our small town when someone becomes noticeably thinner. “He sure has lost a lot of weight.” “Did ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Wegovy (semaglutide) is an FDA-approved medication for chronic weight management. Learn more about Wegovy, including how it works and potential risks.

Patients who took an experimental drug from Eli Lilly & Co. together with Novo Nordisk A/S’s Wegovy maintained muscle while ...

Weight loss drugs cost an average of $1,083 per month or $12,996 per year if you pay full price without any discounts or coupons. If your insurance covers weight loss drugs like Ozempic and Wegovy, ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also cause pregnancy complications and harm some users.

Novo Nordisk has introduced Wegovy, a once-weekly weight-loss injection, in India. The drug aims to manage obesity and reduce ...